What Is Efocipegtrutide?

1. What is efocipegtrutide and how does it work?

Efocipegtrutide combines three hormone signals in one molecule:

• GLP-1 (glucagon-like peptide-1) lowers appetite, slows stomach emptying and raises insulin when blood sugar is high. It is the target of semaglutide.
• GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. Paired with GLP-1, it is the basis of tirzepatide. The GIP guide explains it in more detail.
• Glucagon normally raises blood sugar, but in the liver it also increases fat burning and reduces new fat production. The glucagon guide covers why drug developers now add it to incretins.

Hanmi’s pipeline page says the drug attacks liver fat through three routes at once: lower food intake, more fat burning in the liver (beta-oxidation), and less new fat production (de novo lipogenesis). It also claims a direct effect on hepatic stellate cells, the liver cells that lay down scar tissue, which would address fibrosis rather than only fat (Hanmi pipeline page). That last claim rests on animal studies.

The LAPSCOVERY design

Like Hanmi’s GLP-1 drug efpeglenatide, efocipegtrutide uses the company’s LAPSCOVERY platform. The peptide is attached to the constant region of a human antibody through a non-peptide flexible linker (Hanmi pipeline page). The 2020 EASL poster describes this as a “human IgG Fc fragment via a flexible PEG linker,” with an aglycosylated Fc (one without its usual sugar chains), and says the molecule was “designed and optimized for liver targeted distribution” with a half-life long enough for weekly dosing (EASL 2020 poster).

Fc attachment extends half-life because the body recycles Fc-bearing proteins through a receptor called FcRn instead of breaking them down. For efpeglenatide, built on the same platform, a pooled pharmacokinetic model estimated an effective half-life of about 6–7 days (Choi et al. 2025). A comparable published half-life estimate for efocipegtrutide was not found, so it should not be assumed to be identical.

2. What did the early human studies show?

Two Phase 1 studies are complete. The first-in-human study, NCT03374241, gave single rising doses to 41 healthy adults with obesity in 2018.

The more informative one is the Phase 1b/2a multiple-dose study, NCT03744182. It enrolled 66 non-diabetic adults with obesity (BMI of 30 or more) and fatty liver disease, defined as at least 10% liver fat on MRI-PDFF, an MRI scan that measures the share of the liver that is fat. In each cohort, people were randomized 3:1 to one of five weight-based weekly doses (0.01 to 0.08 mg/kg) or placebo for 12 weeks. Half were women; average age was 46, average BMI 36 and average liver fat 19.2% (EASL 2020 poster).

Source: Abdelmalek et al., EASL 2020 poster. The liver-fat figures are mean relative reductions; the top dose was the only one with statistically significant reductions at both week 8 and week 12. The poster reports the single largest individual reduction as 88%. Doses identify research cohorts, not prescribing guidance.

Three cautions apply. These were nine people per dose, studied for 12 weeks. The results come from a company-authored conference poster, not a peer-reviewed paper. And liver fat on MRI is a surrogate; regulators judge MASH drugs mainly on liver biopsy findings.

Safety in the early study

The poster describes the drug as well tolerated, with mild, dose-dependent gastrointestinal symptoms as the most common adverse events. Two participants developed hyperglycemia (high blood sugar) that resolved after the drug was stopped. No serious adverse events related to the drug occurred (EASL 2020 poster).

Results posted on ClinicalTrials.gov add counts. No participant in any arm had a serious adverse event. Nausea was reported by 10 of the 49 people on efocipegtrutide (rising from 1 of 9 at the lowest dose to 3 of 9 at each of the two highest doses), against 1 of 17 on placebo. Vomiting occurred in 3 of 49 versus 1 of 17 (NCT03744182 results).

The hyperglycemia cases are worth noting because glucagon raises blood sugar. Triple agonists rely on GLP-1 and GIP to offset that effect, and the balance between the three receptors is one of the main design questions for this drug class.

3. What is the HM-TRIA-201 Phase 2b trial?

HM-TRIA-201, registered as NCT04505436, is the trial that will decide whether efocipegtrutide moves to Phase 3. It is a randomized, double-blind, placebo-controlled study in adults with biopsy-confirmed MASH, run in the United States and Korea.

The published design paper describes a 52-week adaptive trial planned for 217 patients. The primary endpoint is complete resolution of steatohepatitis without worsening of fibrosis on liver biopsy. An interim analysis was planned after 15 patients per group finished 26 weeks of treatment, after which one dose group would be dropped based on safety and efficacy, with its patients re-randomized to the two remaining doses. The authors said the adaptive design was meant to reduce the number of people who need liver biopsies (Abdelmalek et al., Contemp Clin Trials 2023).

A 2026 review lists the arms as 2, 4 and 6 mg weekly versus placebo, in people with fibrosis stages F1 to F3 and at least 8% liver fat on MRI-PDFF, with or without diabetes (Tavaglione and Loomba, Cell Rep Med 2026). In December 2024, Hanmi said the trial’s independent data monitoring committee had recommended that all cohorts continue treatment (Hanmi press release, December 2024).

Source: NCT04505436.

When will results come out?

Hanmi announced the trial’s completion in August 2026 and said it would analyze the data before deciding on a global Phase 3 (Nate News, August 2026). A November 3, 2026 report said the results release date had still not been set (Newsway, November 2026). The same report said Hanmi was keeping both in-house development and licensing open as options. Hanmi’s pipeline page lists the drug under partnering opportunities (Hanmi pipeline page).

4. What designations has efocipegtrutide received?

Sources: Hanmi pipeline page; Hanmi press release, December 2024; Nate News, August 2026 for the 2020 Fast Track date.

Fast Track gives a sponsor more frequent FDA meetings and the option of submitting an application in pieces. Orphan drug designation offers development incentives for rare diseases. Neither says the drug works. IPF is a lung-scarring disease; PBC and PSC are chronic diseases of the bile ducts that can lead to liver scarring. Hanmi says expansion into these fibrotic diseases is being investigated, based on animal studies. A ClinicalTrials.gov search on November 8, 2026 found only three efocipegtrutide trials, all in obesity, fatty liver or MASH, and none in IPF, PBC or PSC.

5. What do the animal studies claim?

Hanmi has presented a long series of preclinical posters from 2017 onward, covering NASH, fibrosis, lipids, bone and nerve protection (Hanmi pipeline page). The most recent, at AASLD in November 2024, compared efocipegtrutide with semaglutide and tirzepatide in mouse models of liver inflammation and fibrosis. Hanmi reported that repeated dosing of efocipegtrutide consistently improved inflammation and fibrosis, that the comparators had minimal effect, and attributed the difference to glucagon receptor activation, which semaglutide and tirzepatide lack (Hanmi press release, December 2024).

Animal comparisons like this are hypothesis-generating. Mouse fibrosis models do not reliably predict human biopsy results, and semaglutide is now FDA-approved for MASH on the strength of human biopsy trials (Tavaglione and Loomba 2026). The Phase 2b biopsy data will be the first real test of the fibrosis claim.

6. How has the program unfolded, and where does it fit at Hanmi?

Sources: Hanmi pipeline page; NCT03374241; NCT03744182; NCT04505436; Nate News, August 2026; Hanmi press release, December 2024.

A Phase 2b trial running six years is long. Biopsy-based MASH trials need a liver biopsy to enroll and another at 12 months, which slows recruitment, but Hanmi has not explained this trial’s timeline.

Efocipegtrutide is one of three Hanmi incretin molecules built on the same Fc-linker platform. Efpeglenatide, a pure GLP-1 agonist, won Korean approval for weight management in October 2026. Efinopegdutide, a GLP-1/glucagon dual agonist, is licensed to Merck and reported Phase 2b MASH data in November 2026. Efocipegtrutide is the one Hanmi still owns outright in the liver space, and its Phase 2b result will largely decide whether Hanmi runs a Phase 3 itself or licenses it out, as it did with the other two.

7. How does efocipegtrutide compare with retatrutide and other liver drugs?

Retatrutide’s liver substudy enrolled 98 people with fatty liver from its obesity trial. At 24 weeks, liver fat fell 42.9% to 82.4% depending on dose, versus a 0.3% rise on placebo, and 86% of the 12 mg group reached normal liver fat (under 5%) (Sanyal et al., Nat Med 2024). The liver-fat figures for the two triple agonists look similar, but the studies differed in length, size, doses and population, and efocipegtrutide’s numbers come from a 12-week, 66-person study reported only as a poster.

Hanmi’s other liver candidate, efinopegdutide, is a GLP-1/glucagon dual agonist licensed to Merck. Korean coverage of its Phase 2b results at AASLD in November 2026 reported MASH resolution without fibrosis worsening in 56%, 63% and 61% of the 4, 7 and 10 mg groups versus 13% on placebo, and 53% on semaglutide 2.4 mg (Medipana News, November 2026). That is a different molecule; its results say nothing direct about efocipegtrutide, although they support the broader idea that glucagon-containing agonists can resolve MASH.

Reviewers note that despite approvals of resmetirom and semaglutide for MASH, open questions remain about treatment duration, tolerability and why responses vary so much between people (Tavaglione and Loomba 2026). Those are the questions any new triple agonist will have to answer.

8. What does efocipegtrutide mean for people on GLP-1 drugs?

It is not an add-on to a GLP-1 drug. Efocipegtrutide already includes GLP-1 receptor activity. Combining it with semaglutide, tirzepatide or another incretin would stack the same mechanism and has not been studied.

The side-effect profile is expected to overlap. Nausea and vomiting were the main dose-related events in the early study, as with every GLP-1-based drug. Glucagon activity adds blood sugar as something to watch, since two early participants developed hyperglycemia. Detailed heart-rate and blood-pressure data for efocipegtrutide have not been published beyond the registry’s systolic blood pressure summary.

Weight loss is modest in the available data. The top dose produced about 5% placebo-corrected weight loss in 12 weeks. That is a short study, so it does not show how much weight loss would build up over a year, but Hanmi has not positioned the drug as a competitor to obesity drugs. For weight management, Hanmi’s approved Korean product is efpeglenatide.

Muscle and body composition have not been reported. No body-composition data for efocipegtrutide have been released, so how much of its weight loss is lean mass is unknown. The general evidence on GLP-1 drugs and muscle loss is the best guide for now.

For people with fatty liver on a GLP-1 drug, the approved options are what matter today. Semaglutide 2.4 mg is approved for MASH as Wegovy, and the what is MASH page explains how the disease is staged and treated. Efocipegtrutide is several years and at least one positive Phase 3 program away from being a treatment option.

9. Efocipegtrutide FAQ

• Is efocipegtrutide the same as HM15211?

  Yes. HM15211 is Hanmi Pharmaceutical's development code, and efocipegtrutide is the generic name. Hanmi also calls it the LAPS Triple Agonist. Older papers and posters use HM15211.

• Is efocipegtrutide a weight-loss drug?

  Not primarily. It does cause weight loss, about 5% more than placebo at the top dose in a 12-week early study, but Hanmi has developed it for MASH, a liver disease. Its large trials measure liver biopsy results, not weight. Hanmi has a separate obesity pipeline, including the approved Korean GLP-1 drug efpeglenatide.

• How is efocipegtrutide different from retatrutide?

  Both activate the GLP-1, GIP and glucagon receptors. Retatrutide is Eli Lilly's peptide with a fatty-acid chain, in Phase 3 mainly for obesity. Efocipegtrutide is Hanmi's peptide attached to an antibody Fc fragment, which Hanmi says favors distribution to the liver, and its lead indication is MASH. They have never been compared directly.

• When will Phase 2b results come out?

  No date has been set. The HM-TRIA-201 trial reached its primary completion on June 26, 2026 and completed on July 15, 2026, according to ClinicalTrials.gov. Korean press reports in August and November 2026 said Hanmi had not fixed a date for releasing results, and that Phase 3 plans depend on the analysis.

• Has efocipegtrutide been approved by the FDA?

  No. It has FDA Fast Track designation for MASH, which allows more frequent FDA meetings and rolling review, and orphan drug designations for three rare fibrotic diseases. These are development incentives, not approvals.

• What side effects has efocipegtrutide caused?

  In the 12-week Phase 1b/2a study, the most common side effects were mild gastrointestinal symptoms that rose with dose. Nausea occurred in 10 of 49 people on the drug versus 1 of 17 on placebo, and there were no serious adverse events. Two participants developed high blood sugar that resolved after stopping the drug.

• Is efocipegtrutide related to efinopegdutide?

  They come from the same company and platform but are different molecules. Efinopegdutide is a GLP-1/glucagon dual agonist that Hanmi licensed to Merck in 2020. Efocipegtrutide adds GIP as a third target and remains with Hanmi.

10. Sources